The FTSE 250-listed firm expects revenue to grow between 1% and 2.5%, with adjusted underlying margin up between 18% to 20%.
In the three months to 30 September, group revenue was up 4.6% year-on-year to US$462.9mln, driven by growth in all four divisions – advanced wound care, ostomy care, continence & critical care and infusion devices.
“I am pleased we have reported a solid performance in Q3, but this is a small step on the significant journey ahead of us as we focus on pivoting to sustainable and profitable growth,” said recently appointed chief executive Karim Bitar in a statement.
“As an organisation we need to get closer to patients, to strengthen our innovation pipeline and to drive a relentless focus on execution excellence,” he added.
Shares were up 8% to 198.55p on Wednesday morning.